Formulary Exceptions For Exchange Plans Must Have “Exigent” Process, CMS Says
This article was originally published in The Pink Sheet Daily
Final rule on exchange plan standards for 2015 says enrollees who face serious health risk must have coverage determinations on non-formulary drugs within 24 hours of making request.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.